Nuzenio

Leerink Partners The

Leerink Partners The news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 24 latest news signals 6 publisher sources 100/100 entity strength

Latest news

Akebia Therapeutics Price Target Announced at $1.00/Share by Leerink Partners - MoomooMoomoo · Sat, 08 Aug 2026 00:30:00 GMTLeerink Partners Adjusts Price Target on Cencora to $380 From $368 - MoomooMoomoo · Fri, 07 Aug 2026 13:00:35 GMTLatigo: Goldman Sachs & Co. LLC, Jefferies, Leerink Partners and Guggenheim Securities Are Joint Book-Running Managers for the Offering >LTGO - MoomooMoomoo · Fri, 07 Aug 2026 09:44:36 GMTHALOZYME THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TO OUTPERFORM FROM MARKET PERFORM; RAISES TARGET PRICE TO $110 FROM $83 - BitgetBitget · Fri, 07 Aug 2026 03:04:14 GMTPODD Downgraded by Leerink Partners -- Price Target Lowered to $145 - GuruFocusGuruFocus · Thu, 06 Aug 2026 23:46:27 GMTPROTAGONIST THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TARGET PRICE TO $150.00 FROM $110.00 - BitgetBitget · Thu, 06 Aug 2026 16:16:59 GMTLeerink Partners Adjusts Price Target on Zimmer Biomet to $106 From $90 - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 16:05:19 GMTLeerink Partners Downgrades Insulet to Market Perform From Outperform, Adjusts PT to $145 From $247 - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 13:30:23 GMT

Timeline

Sat, 08 Aug 2026 00:30:00 GMTAkebia Therapeutics Price Target Announced at $1.00/Share by Leerink Partners - Moomoo
Fri, 07 Aug 2026 13:00:35 GMTLeerink Partners Adjusts Price Target on Cencora to $380 From $368 - Moomoo
Fri, 07 Aug 2026 09:44:36 GMTLatigo: Goldman Sachs & Co. LLC, Jefferies, Leerink Partners and Guggenheim Securities Are Joint Book-Running Managers for the Offering >LTGO - Moomoo
Fri, 07 Aug 2026 03:04:14 GMTHALOZYME THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TO OUTPERFORM FROM MARKET PERFORM; RAISES TARGET PRICE TO $110 FROM $83 - Bitget
Thu, 06 Aug 2026 23:46:27 GMTPODD Downgraded by Leerink Partners -- Price Target Lowered to $145 - GuruFocus
Thu, 06 Aug 2026 16:16:59 GMTPROTAGONIST THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TARGET PRICE TO $150.00 FROM $110.00 - Bitget

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Leerink Partners The.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.